Patients with non-erosive reflux disease (NERD) who took the experimental potassium-competitive acid blocker tegoprazan once daily experienced significantly fewer heartburn days than those on placebo, according to phase III data presented at the American College of Gastroenterology annual meeting. The trial, TRIUMpH-NERD, randomized 783 patients to placebo or tegoprazan 50 mg or 100 mg. By week 4, the mean percentage of 24-hour heartburn-free days was 17.3% with placebo, 26.2% with the 50-mg dose, and 30.1% with the 100-mg dose — relative improvements of 51% and 74% over placebo.
Secondary endpoints also favored tegoprazan. Patients on either dose had significantly more days without daytime and nighttime heartburn, and both doses improved regurgitation-free days versus placebo. After a 20-week extension, heartburn-free days reached 47.8% in the 50-mg group and 50.4% in the 100-mg group. The presenter, Dr. Ronnie Fass of Case Western Reserve University, said the findings support tegoprazan as a therapeutic option for NERD, the most common GERD phenotype.
During the discussion, Dr. Henry Parkman of Temple University noted the high placebo response and asked whether lifestyle changes at enrollment might have contributed. Fass acknowledged that placebo effects are not unique to this study but emphasized that the treatment arms remained clearly separated from placebo. Tegoprazan is structurally distinct from other P-CABs and can raise gastric pH above 4 within 45 minutes, with steady state reached in one day. Rates of serious adverse events were similar across arms, and an FDA application for tegoprazan in GERD was submitted in January. The source is MedPage Today's meeting coverage; no independent verification of the data was provided.Strict JSON with exactly keys. Need ensure no extra text. Let's final.{